Completed PHASE2 INTERVENTIONAL NCT00108836

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Sponsor: Novartis Pharmaceuticals

Interventions XBD173

Updated 6 times since 2017 Last updated: May 19, 2010 Started: Mar 31, 2005 Completion: May 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00108836, this PHASE2 trial focuses on Anxiety Disorders and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 6 times since 2005, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anaheim, United States , Atlanta, United States , Dayton, United States , Edmonton, Canada , Fort Meyers, United States , Hamilton, Canada , Hoffman Estates, United States , Kelowna, Canada , Los Angeles, United States , Madison, United States and 13 more locations